MétaCan
Menu
Back to cohort
Record W4291002583 · doi:10.1016/j.gim.2022.06.011

Safety and preliminary efficacy on cognitive performance and adaptive functionality of epigallocatechin gallate (EGCG) in children with Down syndrome. A randomized phase Ib clinical trial (PERSEUS study)

2022· article· en· W4291002583 on OpenAlexaff
Cécile Cieuta‐Walti, Aida Cuenca‐Royo, Klaus Langohr, Claire Rakic, Ma Ángeles López-Vílchez, Julián Lirio, Domingo González‐Lamuño, Teresa Bermejo González, Jordi García García, Maria Rimblas Roure, Ana Aldea‐Perona, Laura Forcano, Maria Gomis‐González, Florence Lacaille, Aimé Ravel, Clotilde Mircher, Hervé Walti, Nathalie Janel, Julien Dairou, Marilyne Lévy, Sophie Durand, Mara Dierssen, Silvia Sacco, Rafael de la Torre, I. Álvarez Guerrico, Albert Goday, Cristina Llop, Julián Mateus, Iris Matilla, Menoyo, Lorena Hernández-Ligero, Marta Drake-Pérez, Neus Pizarro, Alessandro Príncipe, A. Cortesi, Noelia Paredes, Cristina Gómez, Montserrat Graell, Pilar Sáez-López, Rosario Morales Lozano, Constancio Medrano, Maria Teresa Andrade-Navarro, Gema Daza, Sandra Garcia, M. Gayan, Cristina Guerra-Colorado, Beatriz Luna, Enriqueta Maya, Delia Millan, M.V. Camacho Reina, María Teresa Amigo, José Luís Fernández, María García‐Martínez, María del Socorro Pérez-Poyato, Ana Pozueta, Emma Tato, María Teresa Viadero, Magnolia Akkaya, Ségolène Falquero, A Gambarini

Bibliographic record

VenueGenetics in Medicine · 2022
Typearticle
Languageen
FieldMedicine
TopicDown syndrome and intellectual disability research
Canadian institutionsUniversité de Sherbrooke
Fundersnot available
KeywordsTolerabilityPlaceboDiscontinuationMedicineAdverse effectRandomized controlled trialClinical trialPopulationCognitionIncidence (geometry)Internal medicinePediatricsPsychiatryAlternative medicine

Abstract

fetched live from OpenAlex

PURPOSE: Although some caregivers are using epigallocatechin gallate (EGCG) off label in hopes of improving cognition in young adults with Down syndrome (DS), nothing is known about its safety, tolerability, and efficacy in the DS pediatric population. We aimed to evaluate safety and tolerability of a dietary supplement containing EGCG and if EGCG improves cognitive and functional performance. METHODS: A total of 73 children with DS (aged 6-12 years) were randomized. Participants received 0.5% EGCG (10 mg/kg daily dose) or placebo for 6 months with 3 months follow up after treatment discontinuation. RESULTS: In total, 72 children were treated and 66 completed the study. A total of 38 participants were included in the EGCG group and 35 in the placebo group. Of 72 treated participants, 62 (86%) had 229 treatment-emergent adverse events (AEs). Of 37 participants in the EGCG group, 13 (35%) had 18 drug-related treatment-emergent AEs and 12 of 35 (34%) from the placebo group had 22 events. In the EGCG group, neither severe AEs nor increase in the incidence of AEs related to safety biomarkers were observed. Cognition and functionality were not improved compared with placebo. Secondary efficacy outcomes in girls point to a need for future work. CONCLUSION: The use of EGCG is safe and well-tolerated in children with DS, but efficacy results do not support its use in this population.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.006
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.301
Threshold uncertainty score0.687

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0060.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.077
GPT teacher head0.392
Teacher spread0.315 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations34
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueGenetics in MedicineSame topicDown syndrome and intellectual disability researchFrench-language works237,207